Cancer immunotherapy enhancing immune responses to fight cancer cells. As one kind of immunitherapies, chimeric antigen receptor T cells (CAR-T) therapy was launched in America at the year 2017 and had been indicated to treat refractory and relapse B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. The CAR-T therapy involves modifing T cells to recognize cancer cells more effectively. Scientists harvest T cells (derived from T cells in a patient's own blood), genetically alter them, then infuse the resulting CAR-T cells into patients to attack their own cancer cells. With enhacing immune responses, cytokine release syndrome and neurological toxicity commonly occurred as adverse events. Patients may presented with fever, hypotension, hypoxemia, confusional state change with seizure episodes. In this article, we briefly introduce the CAR-T therapy and its adverse events with an eye toward promting the role of nurses in caring for these hightly voulnerable patients before, during, and after CAR-T therapy.